The US Patent and Trademark Office has issued US Patent No. 10,933,204, titled “Prescription bottle cap capable of administering opioid overdose reversal agent” to CounterAct for its naloxone nasal spray cap, the company said. CounterAct is developing the nasal spray cap, which is designed to snap onto the top of a prescription pill bottle, for the reversal of opioid overdose.
According to CounterAct, “the patent covers technology that will revolutionize current and future patients’ consumption of chronic pain treatment with a high potential for overdose or misuse. This technology offers a patient friendly antidote conveniently delivered as a nasal spray integrated into the cap of the standard pill medicine. The proprietary technology will provide patients, prescribers, and care takers the peace of mind for a rapid administration of rescue medication directly co-prescribed with potent potentially addictive medication which often trigger an anaphylaxis reaction or worse an overdose.”
In October 2018, the company announced that it had met with the FDA and that the agency had provided clarification on how to move forward with clinical development of the device, including specifying spray characteristics and asking for bioavailability and human factors studies.
CounterAct Co-Founder Todd Pizitz commented, “We are pleased to strengthen our intellectual property protection with the addition of this US patent. Following a successful Pre-IND meeting with the USFDA, we have engaged in advance to discussions with leaders in the device and drug development industry to bring this technology to market. This new patent provides a strong path forward to partner with key stake holders to bring this life saving technology to patients to fulfill this unmet need.”
